Harsha K Rajasimha, Ph.D.
Dr. Harsha Karur Rajasimha is a genomics scientist, social entrepreneur and co-founder of the Organization for Rare Diseases India (ORDI). At ORDI, Dr. Rajasimha is responsible for the overall vision, research, strategy, formation of advisory boards, international collaborations, web content development and grant proposals.
Dr. Rajasimha is a life sciences solutions consultant for Dell and co-directs the center for metabolic and rare diseases at George Mason University where he leads research in rare disease database integration, policy frameworks, best practices guidelines for diagnosis and screening of rare diseases in USA and how they can be adapted to countries such as India. He is also founder president of Jeeva informatics solutions, a genomics bigdata analytics company based in Maryland, USA and serves on the executive advisory board of a number of companies.
Dr. Rajasimha has over 15 years work experience and 15 peer-reviewed publications in interdisciplinary projects involving genomics, BigData integration and analysis at National Institutes of Health, US FDA, Strand Genomics Inc. and Virginia Bioinformatics Institute. His research work has focused on the genomics and systems biology of diseases including rare genetic diseases, Cancer, Infectious, mitochondrial, and retinal degenerative diseases. Harsha earned his MS in Computer Science (2004) and PhD in Genetics, Bioinformatics and Computational Biology at Virginia Tech (2007).
Prasanna Kumar Shirol
Prasanna Kumar Shirol serves as a founder member of the Organization for Rare Diseases in India and a Founder Former President of LSD Support Society (Lysosomal Storage Disorder Support Society),This is the first National Level Parents support group for children suffering from ULTRA RARE Diseases in India. The society initiated observing International Rare Disease day for the first time in India on a national scale under his leadership. He has worked extensively to create awareness on LSD and Rare disease in India. He has represented India in various conferences and meetings internationally .developed a strong network of international Parent and Rare disease groups.
Prasanna Kumar academically an Post Graduate in Business Management has over 16 years of sales experience in telecom and consumer industry. Worked with companies like Sony, Reliance, Bharti etc. He has a experience in launching product and services. Personally, he is married to Sharada and has a 14 year daughter. Nidhi is India’s first Pompe Patient and also runs Pompe Foundation supporting Pompe Patients in India.
Contact: Mobile: +91 998013330, Email: firstname.lastname@example.org
Dr. Madhuri Hegde, Ph.D., FACMG
Dr. Hegde is the Professor, Human Genetics and Executive Director of Emory Genetics Laboratory. Her areas of specialty and interest are muscular dystrophy, mental retardation, and novel and high throughput methodologies to detect sequence variation. The focus of her laboratory is to develop and perform comprehensive mutation analysis and interpretation for complex or challenging genetic disorders using multiple approaches. The primary focus of her clinical work is the development of high-throughput next generation sequencing strategies for rare disorders using sequence capture technologies, robotics, whole exome and genome sequencing,oligonucleotide array platforms, robotics. Her research is focused on gene discovery and functional analysis of sequence variants in disease associated genes specifically muscular dystrophies and translating what is learned in the basic research laboratory to clinical practice. She received a B.Sc. and a M.Sc. from the University of Bombay, India, and a Ph.D. from the University of Auckland, New Zealand. She has post doctoral studies at Baylor College of Medicine and is board certified in Clinical Molecular Genetics.
A pathfinder of Sorento with ever-futuristic vision, ability to think beyond, inquisitive mind and deep commitment to healthcare.
Over 22 years’ experience in Pharmaceutical Marketing and Healthcare Communications. Formerly headed category teams and market research in big Indian pharmaceutical Companies. Trained as a Microbiologist and with a Master’s in Marketing Management Sangeeta has crafted strategies for more than 100 healthcare brands.
Spearheaded new divisions of Sorento viz. Xrays Biocom – Scientific Communication, AXess – Patient Management and treatment adherence. With an ability to conceptualize and execute complex solution architects has devised new products and services for Sorento
Ravinandan M E, MTech,(Ph.D.)
A Technologist, Dreamer, Doer. Loves to be in thick of things. Wishes to make a positive impact with the help of technology. On a mission to democratize technologies. A teetotaller, but gets a high when ever gives back to society.
Evangelist of Lean principles and Rare diseases awareness.
Dr. Vijay Chandru, Ph.D.
Dr. Vijay Chandru is an alumnus of BITS Pilani and UCLA where he trained in Electrical Engineering and went on to get a doctorate from MIT in Decision Sciences. Vijay is an academic and an entrepreneur. His academic career in mathematical and computational sciences has spanned over thirty years as a research scientist and professor at Purdue University, Indian Institute of Science, and University of Pennsylvania. He is a fellow of the Indian academies of science and engineering and an adjunct professor of the International Centre for Theoretical Sciences (TIFR) in Bangalore.
As an entrepreneur, Dr Chandru is a founder CEO of the translational biology company Strand Life Sciences for which he has been recognized as a Technology Pioneer by the World Economic Forum in 2006. Dr Chandru was a founder of Picopeta Simputers which commercialized the handheld computer called the Simputer. He received the Dewang Mehta award for innovation in information technology from the Ministry of Communications and Information Technology in 2001 for this work with the Simputer.
Dr Chandru serves on the Global Advisory Board of the MIT Enterprise Forum and the Governing Board of the Indo-US Science and Technology Forum. In 2003, Dr Chandru helped start the Association for Biotech Led Enterprises (ABLE), the apex body of the Indian Biotech Sector, and has served as the Founder Secretary (2003-2006) and as President (2009-2012). Dr Chandru is a member of the Vision Groups for Biotechnology and Science & Technology for the state of Karnataka.
Dr. Preveen Ramamoorthy, Ph.D
Dr. PreveenRamamoorthy founded the Molecular Diagnostics department at National Jewish Health, Denver in 2007. Currently, he directs the translation of biomarkers into molecular diagnostic tests at the Advanced Diagnostic Laboratories at National Jewish Health. His laboratory has launched numerous rapid diagnostic, prognostic and companion diagnostic tests and is serving patients and physicians at National Jewish Health and the U.S.A.
Prior to joining National Jewish Health Dr. Ramamoorthy was involved in the development of viral vaccines, cancer vaccines and monoclonal antibodies at MedImmune. Dr. Ramamoorthy completed his post-doctoral fellowship at Walter Reed Army Institute of Research, Silver Spring in genomics and molecular diagnostics. During his Ph.D at Clemson University Dr. Ramamoorthy co-invented a prolactin receptor antagonist, a molecular therapeutic drug for breast cancer. Dr. Ramamoorthy obtained his Master’s in Medical Microbiology at the University of Madras before he embarked upon his Ph.D program at Clemson University.
Dr. Ramamoorthy is passionately interested in the development of genome based diagnostic tests, integrating them into personalized medicine clinical programs and enabling physicians and patients to prevent, manage and treat diseases. In addition, Dr. Ramamoorthy has social entrepreneurial aspirations in creating and developing diagnostics solutions suited for resource insufficient settings such as developing countries. He is convinced that the bi-directional flow of healthcare ideas and innovations from developing countries to developed countries will not only benefit health care sector of developing countries but also developed countries.